Medical College of Georgia

 Technology Transfer and Economic Development

A-Z Index  |  MCG Home  |  Site Search

 

Tech Transfer Office
What is technology transfer
About the office
Vision, goals, functions
Staffing
Organization
IP Committee
Tech Transfer "101"
Patents
Copyrights, etc.
The Process at MCGNew!
Revenue sharing
Newsletter
MCG Incubator
Overview
Facilities & Benefits
Admissions
Photo Album
Preferred Providers
Advisory Board
About Us
MCG Policies
Intellectual Property
Conduct of Research
Conflict of Interest
Forms
Invention Disclosure
Materials Transfer
Confidential Disclosure
Corporate Participation
About MCG
Accessing MCG
Patent portfolio
Technologies Available for License
Life Sciences Business Center
Special Initiatives
Interesting Links
 

 

Technology Transfer “101”

Patents

A patent (a right defined in Article I, section 8 of the United States Constitution) is a mechanism by which inventors can exclude others from making, using or selling their invention. The invention can be a new product or article (a manufacture), an apparatus or device (a machine), an action performed in order to yield a specific result (a process), or a new chemical (a composition of matter). Current patent law also allows for patents on life forms and software under certain circumstances.  Significant improvements over a patent already in existence, or an entirely new use for an existing patent also can be protected. The U.S. uses a “first-to-invent” system for determining the true inventor, whereas other countries use a “first-to-file” system.

A patent is awarded by the federal government if the inventor can prove that the invention is unique, has utility, and is not obvious to someone with “ordinary skill in the art”. The Department of Commerce, the agency that administers the U.S. Patent and Trademark Office ("PTO"), has awarded more than 6 million patents since the office was founded in the late 1700s. The current rate of patent awards is more than 160,000 per year.

Time between filing the application and seeing the patent issue averages about 2 years, but fields such as biotechnology often have patents under process and review for more than 3 or 4 years. During this period of “patent prosecution” there usually is a volley of exchanges between the PTO rejecting some aspect of the application and the inventor’s legal representative attempting to disprove the allegations or grounds for rejection. 

When it issues, a patent has a lifetime of 20 years from the filing date.  Note that a patent is an exclusionary right. It affords the owner of the patent the opportunity to prevent others from making, using or selling the invention. It may not actually allow you to practice your own invention if someone has another patent that dominates yours. After the twenty-year period (to the day) of exclusive control, anyone can practice the invention without fear of being challenged by the inventor.

Most academic institutions deal with the standard type of patent called a “utility” patent. There also is a “design” patent that is used to protect the appearance or non-functional aspects of an invention. It is reserved for the ornamental features only, and it is often easy to “invent around” or circumvent the intent of such protection.

The patenting process is expensive. MCG contracts with outside patent attorneys to write the application (with the input and guidance of the inventors on the technological aspects) and to navigate it through the patent office. Average costs for filing and prosecuting a typical utility patent approach $15,000, and can often be double that figure.  Once a patent is actually awarded, there also are maintenance fees at years 3, 7, and 11 that add several more thousand dollars to the bottom line. Foreign filings in the standard set of industrialized nations usually cost about 10 times more than domestic filings, so academic institutions typically only file in other countries if there is a licensee in place ready to absorb those costs.

Since one can file for a U.S. patent only within a one-year period after any type of pubic disclosure (one that contains detail sufficient for another individual to build the invention or duplicate the process) or offer for sale, MCG researchers and inventors should pay close attention to their presentation and publication plans. 

Note that the public distribution of abstracts of presentations before meetings are held,  and the web-based distribution of articles by journals before the publication is mailed out to subscribers, will start the one-year clock running earlier than one often assumes.
 

The PTO is very strict on this timing requirement, and the 12-month rule means exactly 365 days from the point of disclosure or offer for sale.  Foreign filings have an absolute requirement for novelty, and any pubic disclosure normally will eliminate the possibility of ever subsequently filing in other countries. There is an exception to this rule, however, since one can file in the U.S. and then submit a Patent Cooperation Treaty application, or PCT filing, within one year of filing in the U.S. This allows you to then make public presentations while to consider which foreign countries you wish to have patent protection in, and submit the country-by country national filings at a later date.

Publishing and patenting need not be mutually exclusive. Filing for a patent does not necessarily impede the scientific process. In fact, patenting and publishing can complement each other. However, the sequence of actions and the timing that will best serve the inventor, the institution, and society need to be given serious consideration. The position of the OTTED is that the ultimate decision on whether or not to publish rests with the inventor. When in doubt, please consult the tech transfer office for assistance or clarification.

Most of the comments above pertain to a regular patent filing. The PTO has another route that is simpler and affords another way to enter the patenting process. A provisional patent application can be based on a manuscript or detailed drawings or even a grant proposal. For a modest fee, one can either submit that material or a rough draft of a patent application without developing claims or full detail. These applications are not reviewed, but rather only serve as a mark in time, and reserve a place in queue at the PTO. After a one-year period, the provisional application must be converted to a regular, fully-detailed application or it will be abandoned. In a way, this extends the 20-year life of a patent by another year. It is the preferred method of protection when a public presentation is going to be made before a full or regular application can be developed by a patent attorney.


Copyright 2007
Medical College of Georgia
All rights reserved

Research  |  Medical College of Georgia
Please email comments, suggestions or questions to:
 aafzalpurkar@mcg.edu, or call (706) 721-1376

 

12/12/06